<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00439179</url>
  </required_header>
  <id_info>
    <org_study_id>BrUOG-PA-205</org_study_id>
    <nct_id>NCT00439179</nct_id>
  </id_info>
  <brief_title>A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema</brief_title>
  <acronym>BrUOG-PA205</acronym>
  <official_title>BrUOG-PA-205 A Phase I Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema GSK Study ProtocolGSK #103556</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary
      Cancer Schema
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this phase I study is to determine the safety, tolerability and
      optimal tolerated regimen of GW572016 when combined with gemcitabine and with the combination
      of gemcitabine and oxaliplatin. Three to six patients will be treated at each dose level to
      assess toxicity. To better assess the safety at the final dose level in both Stage I and
      Stage II, the number of patients in the cohort at the Maximum Tolerated Dose for both Stages
      will be expanded to 10. Therefore approximately 34-37 patients will be treated on this study.

      Trial finished and no further data will be collected.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity (Number of Patients Who Experiened DLTs)</measure>
    <time_frame>until death, approximately 2 years</time_frame>
    <description>To determine the safety and tolerability of GW572016 when administered with gemcitabine and the combination of gemcitabine and oxaliplatin in patients with advanced pancreaticobiliary cancers. Numbers below are DLTs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Experienced a Partial Response</measure>
    <time_frame>every two months until progression</time_frame>
    <description>To assess clinical activity of GW572016 with gemcitabine and with the combination of gemcitabine and oxaliplatin in patients with advanced pancreaticobiliary cancers.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Metastatic Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly gem + GW572016, 1000mg/day (combination)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly gem + GW572016, 1500 mg/day (combination)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GEMOX + GW572016 1000 mg/day (combination)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GEMOX + GW572016 1500 mg/day (combination)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cohort 1</intervention_name>
    <description>Weekly gem + GW572016, 1000mg/day (combination)</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cohort 2</intervention_name>
    <description>Weekly gem + GW572016, 1500 mg/day (combination)</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cohort 3</intervention_name>
    <description>GEMOX + GW572016 1000 mg/day (combination)</description>
    <arm_group_label>cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cohort 4</intervention_name>
    <description>GEMOX + GW572016 1500 mg/day (combination)</description>
    <arm_group_label>cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients are required to have histologically or pathologically confirmed, metastatic
             or locally advanced adenocarcinoma of the pancreas or biliary tree

          -  No prior systemic chemotherapy for locally advanced or metastatic pancreaticobiliary
             cancer. No prior EGFR inhibitors.

          -  ECOG performance status 0-2 retain ability to swallow oral medications

          -  Age &gt; 18, non pregnant. Because no dosing or adverse event data are currently
             available on the use of GW572016 in patients &lt;18 years of age, children are excluded
             from this study.

          -  The effects of GW572016 on the developing human fetus at the recommended therapeutic
             dose are unknown. For this reason, women of child-bearing potential and men must agree
             to use adequate contraception (hormonal or barrier method of birth control or
             abstinence) prior to study entry and for the duration of study participation. Should a
             woman become pregnant or suspect she is pregnant while participating in this study,
             she should inform her treating physician immediately.

        A female is eligible to enter and participate in the study if she is of:

          1. Non-childbearing potential (i.e., physiologically incapable of becoming pregnant),
             including any female who:

               -  Has had a hysterectomy,

               -  Has had a bilateral oophorectomy (ovariectomy),

               -  Has had a bilateral tubal ligation, or

               -  Is post-menopausal(a demonstration of total cessation of menses for ³1 year).

          2. Childbearing potential, has a negative serum pregnancy test at screening, and agrees
             to one of the following:

               -  Intrauterine Device (IUD),

               -  Vasectomized partner who is sterile prior to the female subject's entry and is
                  the sole sexual partner for that female.

               -  Complete abstinence from sexual intercourse for two weeks before exposure to
                  investigational products, throughout the clinical trial, and for at least one
                  week after the last dose of investigational product.

               -  Double barrier contraception (condom with spermicidal jelly, foam, suppository,
                  or film; diaphragm with spermicide; or male condom and diaphragm)

                    -  Adequate hematologic function: ANC≥1500/ul,platelets≥100,000/ul,hemoglobin 8

                    -  Adequate hepatic function with total bilirubin ≤ 1.5mg/dL and ALT or AST ≤
                       2x ULN. (Patients with liver metastases may have AST/ALT less than or equal
                       to 5x upper limit of normal). Patients with elevated bilirubin secondary to
                       biliary obstruction that have subsequently been stented may enter the
                       protocol with a bilirubin of &lt; 2.0 as long as the bilirubin is falling.

                    -  Adequate renal function: (creatinine ≤1.5mg/dL or estimated creatinine
                       clearance greater than 60ml/min calculated by the Cockcroft Formula).

                    -  Cardiac ejection fraction within the institutional range of normal as
                       measured by echocardiogram or MUGA scan. Note that baseline and on treatment
                       scans should be performed using the same modality and preferably at the same
                       institution.

                    -  No peripheral neuropathy for patients who receive oxaliplatin.

                    -  Life expectancy of at least 12 weeks

                    -  Signed informed consent

        Exclusion Criteria:

        A subject will not be eligible for inclusion in this study if any of the following criteria
        apply:

          -  Prior treatment with GW572016 or any EGFR targeting therapies.

          -  Prior treatment with systemic chemotherapy for metastatic pancreaticobiliary cancer.

          -  Evidence of brain metastases or leptomeningeal disease

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Known contraindications to the use of oxaliplatin or gemcitabine.

          -  History of allergy to platinum compounds in patients receiving oxaliplatin. Amendment
             #2 4/28/05

          -  The subject has a known immediate or delayed hypersensitivity reaction or idiosyncrasy
             to drugs chemically related to the study drug.

          -  HIV-positive patients receiving combination anti-retroviral therapy are excluded from
             the study because of possible pharmacokinetic interactions with GW572016

          -  Participation in any investigational study within 28 days prior to study enrolment

          -  Any major surgery (insertion of a vascular access device is not considered a major
             surgery), hormonal therapy (other than replacement), chemotherapy or radiotherapy
             within the last 4 weeks and/or not recovered from prior therapy within the last 4
             weeks and/or not recovered from prior therapy.

          -  Pregnant or lactating females are excluded from this study because GW572016 is member
             of the 4-anilinoquinazoline class of kinase inhibitors with the potential for
             teratogenic or abortifacient effects. Because there is an unknown but potential risk
             for adverse events in nursing infants secondary to treatment of the mother with
             GW572016, breastfeeding should be discontinued if the mother is treated with GW572016.

          -  Malabsorption syndrome disease significantly affecting gastrointestinal function or
             major resection of the stomach or small bowel that could affect absorption of
             GW572016.

          -  Any unresolved bowel obstruction.

          -  The patient has inadequate venous access in the clinical judgment of the investigator
             or designated clinical staff.

          -  The patient is taking any medication on the prohibited medications list in Section
             10.2 Patients requiring oral anticoagulants (coumadin, warfarin) are eligible provided
             there is increased vigilance with respect to monitoring INR. If medically appropriate
             and treatment available, the investigator may also consider switching these patients
             to LMW heparin, where an interaction with GW572016 is not expected.

          -  Patients may not be receiving any other investigational agents or receiving concurrent
             anticancer therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>howard Safran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>brown University oncology group</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2007</study_first_submitted>
  <study_first_submitted_qc>February 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2007</study_first_posted>
  <results_first_submitted>May 13, 2013</results_first_submitted>
  <results_first_submitted_qc>April 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 5, 2014</results_first_posted>
  <last_update_submitted>July 15, 2014</last_update_submitted>
  <last_update_submitted_qc>July 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brown University</investigator_affiliation>
    <investigator_full_name>howard safran</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pancreatic Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients with both pancreatic and bilary cancer were enrolled</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1</title>
          <description>Cohort 1: Weekly gem + GW572016, 1000mg/day. (combination)</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2</title>
          <description>Cohort 2: Weekly gem + GW572016, 1500 mg/day. (combination)</description>
        </group>
        <group group_id="P3">
          <title>Cohort 3</title>
          <description>Cohort 3: GEMOX + GW572016 1000 mg/day. (combination)</description>
        </group>
        <group group_id="P4">
          <title>Cohort 4</title>
          <description>Cohort 4: GEMOX + GW572016 1500 mg/day.(combination)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3">1 with biliary</participants>
                <participants group_id="P2" count="13">2 with biliary</participants>
                <participants group_id="P3" count="6">2 with biliary</participants>
                <participants group_id="P4" count="5">2 with biliry</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>* 1 pt inelig, 1 pt numb not used</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>participant number correlates to all enrolled patients treated on this study as a whole which is the way in which the abstract was written and therefore how these results are entered</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1</title>
          <description>Cohort 1: Weekly gem + GW572016, 1000mg/day.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2</title>
          <description>Cohort 2: Weekly gem + GW572016, 1500 mg/day.</description>
        </group>
        <group group_id="B3">
          <title>Cohort 3</title>
          <description>Cohort 3: GEMOX + GW572016 1000 mg/day.</description>
        </group>
        <group group_id="B4">
          <title>Cohort 4</title>
          <description>Cohort 4: GEMOX + GW572016 1500 mg/day</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.6" spread="17"/>
                    <measurement group_id="B2" value="66" spread="11"/>
                    <measurement group_id="B3" value="61.5" spread="6"/>
                    <measurement group_id="B4" value="64.2" spread="12"/>
                    <measurement group_id="B5" value="63.7" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Toxicity (Number of Patients Who Experiened DLTs)</title>
        <description>To determine the safety and tolerability of GW572016 when administered with gemcitabine and the combination of gemcitabine and oxaliplatin in patients with advanced pancreaticobiliary cancers. Numbers below are DLTs</description>
        <time_frame>until death, approximately 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohorts 1</title>
            <description>Cohort 1: Weekly gem + GW572016, 1000mg/day.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>weekly gem+ GW572016, 1500mg/day</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>GEMOX+ GW572016 1000mg day</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>GEMOX+ GW572016 1500mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity (Number of Patients Who Experiened DLTs)</title>
          <description>To determine the safety and tolerability of GW572016 when administered with gemcitabine and the combination of gemcitabine and oxaliplatin in patients with advanced pancreaticobiliary cancers. Numbers below are DLTs</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Experienced a Partial Response</title>
        <description>To assess clinical activity of GW572016 with gemcitabine and with the combination of gemcitabine and oxaliplatin in patients with advanced pancreaticobiliary cancers.</description>
        <time_frame>every two months until progression</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohorts 1</title>
            <description>Cohort 1: Weekly gem + GW572016, 1000mg/day.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Cohort 2: Weekly gem + GW572016, 1500 mg/day.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>Cohort 3: GEMOX + GW572016 1000 mg/day.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>Cohort 4: GEMOX + GW572016 1500 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Experienced a Partial Response</title>
          <description>To assess clinical activity of GW572016 with gemcitabine and with the combination of gemcitabine and oxaliplatin in patients with advanced pancreaticobiliary cancers.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1</title>
          <description>Cohort 1: Weekly gem + GW572016, 1000mg/day.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2</title>
          <description>Cohort 2: Weekly gem + GW572016, 1500 mg/day.</description>
        </group>
        <group group_id="E3">
          <title>Cohort 3</title>
          <description>Cohort 3: GEMOX + GW572016 1000 mg/day.</description>
        </group>
        <group group_id="E4">
          <title>Cohort 4</title>
          <description>Cohort 4: GEMOX + GW572016 1500 mg/day</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Gr 3 Infection</sub_title>
                <description>Gr 2 Fever, Gr 1 Chills &amp; Hyperbillirubinemia</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>DLT</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Howard Safran, MD</name_or_title>
      <organization>BrUOG</organization>
      <phone>4018633000</phone>
      <email>Hsafran@lifespan.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

